Konfident302 is made and published by Snapiot Inc. AppBrain is an independent app data site and isn't affiliated with Snapiot Inc. The app name, icon, screenshots and description belong to Snapiot Inc and are shown as published on the App Store.
AppBrain's verdict
- Last updated
- March 28, 2025
Rankings
App Store top chartsApp Store Rankings for Konfident302
Competitors
Similar apps and more from Snapiot IncReleases
Updates seen on the App Store- Version
- 8.1.0
- Launched
- August 2022
No changelog data
User feedback
Ratings and reviews on the App StoreComments on Konfident302 for iOS
We don't have enough comments to show example comments. Please check back later.
Technology
Found in the app by AppBrain- Price
- Free
- App size
- 22.8 MB
- Content rating
- Medium
Technologies used by Konfident302
About the app and developer
About Konfident302
Konfident302 is a medical app developed by Snapiot Inc.
User Ratings
The app has no ratings yet.
App Information
Konfident302 is freely available from the App Store. The app size is 22.82 MB. The latest version available is 8.1.0. The last update was on March 28, 2025.
Technical Requirements
The app has a content rating of Medium Maturity. The app has been available on the App Store since August 2022.
Developer information for Snapiot Inc
Address:
Frequently asked questions about Konfident302
Is Konfident302 free?
Yes. Konfident302 is free on the App Store.
Is Konfident302 still available?
Yes. Konfident302 is on the App Store, and the last update we saw was on March 28, 2025.
How large is Konfident302?
Konfident302 is 22.82 MB.
Is Konfident302 suitable for children?
App Store gives Konfident302 a medium maturity rating, so it is not meant for young children.
Who made Konfident302?
Konfident302 was developed by Snapiot Inc. It is listed in the medical category on the App Store.
What are the best alternatives to Konfident302?
People looking at Konfident302 also look at these medical apps: HAE Companion, HAE TrackR, HAE & Me, Progressive Identifier for ECP, St. George Marathon.